# Carvedilol and Alverine in Portal Hypertension

> **NCT06696248** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Shanghai Changzheng Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Hypertension, Portal

## Interventions

- **DRUG:** Carvedilol and alverine

## Key facts

- **NCT ID:** NCT06696248
- **Lead sponsor:** Shanghai Changzheng Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-11-15
- **Primary completion:** 2025-09-30
- **Final completion:** 2025-09-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-11-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06696248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06696248, "Carvedilol and Alverine in Portal Hypertension". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06696248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*